Scleroderma, Diffuse

Immunology·MeSH: Scleroderma, Diffuse

Prevalence

200.0 / 100K

4 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Compare drugs

oral ifetroban vs rapcabtagene autoleuceloral ifetroban vs novel oral therapy targeting fatal form of heart disease in duchenne muscular dystrophy patients

Frequently asked questions

How many drugs are in development for Scleroderma, Diffuse?

BioSniper tracks 4 drugs in development for Scleroderma, Diffuse across 2 companies.

How many clinical trials target Scleroderma, Diffuse?

There are 2 clinical trials targeting Scleroderma, Diffuse tracked by BioSniper.

What is the prevalence of Scleroderma, Diffuse?

The estimated prevalence of Scleroderma, Diffuse is approximately 200.0 per 100,000 population.

Deep-dive into Scleroderma, Diffuse

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Scleroderma, Diffuse — Drugs in Development & Clinical Trials | BioSniper